{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:20:18Z","timestamp":1789968018192,"version":"4.0.1"},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DDDT"],"DOI":"10.2147\/dddt.s142406","type":"journal-article","created":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T18:50:10Z","timestamp":1534791010000},"page":"2577-2590","source":"Crossref","is-referenced-by-count":63,"title":["Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib"],"prefix":"10.2147","volume":"Volume 12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3905-0921","authenticated-orcid":true,"given":"G\u00fcnter","family":"Krause","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4772-5220","authenticated-orcid":true,"given":"Floyd","family":"Hassenr\u00fcck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2018,8]]},"container-title":["Drug Design, Development and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=43792","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=43792","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T18:50:11Z","timestamp":1534791011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/copanlisib-for-treatment-of-b-cell-malignancies-the-development-of-a-p-peer-reviewed-article-DDDT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/dddt.s142406","relation":{},"ISSN":["1177-8881"],"issn-type":[{"value":"1177-8881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}